Evidence map›Paper›PMID 12652161›Full record

ReviewHeart failure reviews2003

Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction.

Todd J Anderson

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Heart failure reviews, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02254850 (The Mesoglycan and Vascular Reactivity in the Metabolic Syndrome), which is not on this map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02254850 phase4completednot on this mapstarted 2013, after this paper: background citation

The Mesoglycan and Vascular Reactivity in the Metabolic Syndrome

TypeinterventionalSponsorFederico II UniversityRan2013 to 2014Enrolled30ConditionsMetabolic SyndromeArmsFlow Mediated Dilation, Mesoglycan, Placebo
3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 155 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Todd J AndersonDepartment of Medicine, University of Calgary, Calgary, AB, Canada. todd.anderson@calgaryhealthregion.ca
University of Calgary · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The endothelium plays a key role in vascular homeostasis through the release of a variety of autocrine and paracrine substances, the best characterized being nitric oxide. A healthy endothelium acts to prevent atherosclerosis development and its complications through a complex and favorable effect on vasomotion, platelet and leukocyte adhesion and plaque stabilization. The assessment of endothelial function in humans has generally involved the description of vasomotor responses, but more widely includes physiological, biochemical and genetic markers that characterize the interaction of the endothelium with platelets, leukocytes and the coagulation system. Stable markers of inflammation such as high sensitivity C-reactive protein are indirect and potentially useful measures of endothelial function for example. Attenuation of the effect of nitric oxide accounts for the majority of what is described as endothelial dysfunction. This occurs in response to atherosclerosis or its risk factors. Much remains to be learned about the molecular and genetic pathophysiological mechanisms of endothelial cell abnormalities. However, pharmacological intervention with a growing list of medications can favorably modify endothelial function, paralleling beneficial effects on cardiovascular morbidity and mortality. In addition, several small studies have provided tantalizing evidence that measures of endothelial health might provide prognostic information about an individual patient's risk of subsequent events. As such, the sum of this evidence makes the clinical assessment of endothelial function an attractive surrogate marker of atherosclerosis disease activity. The review will focus on the role of nitric oxide in atherosclerosis and the clinical relevance of these findings.

Indexed as

Coronary Artery DiseaseC-Reactive ProteinEndothelium, VascularHomeostasisHumansLeukocytesNitric OxidePlatelet AdhesivenessVasomotor SystemC-Reactive ProteinNitric Oxide

Identifiers

PMID12652161
OpenAlexW1582020189

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.